FA Corporation
FA Corporation
Explore linked clinical trials.3 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of 2910 nm Fiber Laser Resurfacing and Laser-Coring | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Skin and Connective Tissue Diseases, connective tissue disorder, cutis laxa, hereditary disease, hereditary skin disorder, skin disorder | Active, not recruiting | Not applicable | 2026-09-01 | NCT07254884 | |
| Safety and Efficacy of a 2,910 nm Fractional Ablative Fiber Laser (UltraClear®) for Improvements of Skin Laxity and Lifting of the Lower Face, Submental, and Neck Treatment Areas | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Skin and Connective Tissue Diseases, connective tissue disorder, cutis laxa, hereditary disease, hereditary skin disorder, skin disorder | Not yet recruiting | Not applicable | 2026-08-12 | NCT07759817 | |
| 2910 nm Erbium-Doped Fluoride Fiber Glass Laser for the Treatment of Advanced Perioral Lines and Wrinkles | Lines Skin; Photodamaged Skin; Rhytids; Wrinkles and Rhytides | Recruiting | Not applicable | 2025-10-29 | NCT07222397 |